SCP SCIENCE expanded their DigiPREP Digestion Systems product line to include three new products.
President Barack Obama said he is allowing federal taxpayer dollars to fund significantly broader research on embryonic stem cells.
Chemicals present in cranberries prevent infection-causing bacteria from attaching to the cells that line the urinary tract.
TetraLogic Pharmaceuticals announced that they executed a license agreement under which they acquired exclusive worldwide rights from Harvard University to commercialize novel necrostatin compounds and related drug discovery technology developed at Harvard Medical School.
Applied Biosystems and the Translational Genomics Research Institute announced a strategic alliance designed to accelerate research into complex diseases and medical conditions.
A group of academic and industry scientists has issued a challenge to researchers in the field of HIV/AIDS: find a way to effectively purge latent HIV infection and eliminate the need for chronic, suppressive therapy to control this disease.
PTI Packaging Systems announced Toyo Machine Manufacturing will exhibit stick packaging machinery at Interphex 2009.
Members of the RFID Security Alliance (RFIDSA) are participating in a panel discussion at the 2009 INTERPHEX conference titled ‘Securely Implementing RFID in the Pharmaceutical Supply Chain.’
Watson-Marlow’s peristaltic technology simplifies cleaning validation and enhances the integrity of high purity upstream processes, purification, and fill/finish applications.
Using the ActiPix Dissolution Imager from Paraytec, formulation scientists are able 'to see' in real-time what is happening at a tablet surface during the process of dissolution.
Eksigent introduced the cHiPLC-nanoflex System, delivering improved reproducibility and ease of use to proteomics research.
The AccuTOF-GCv mass spectrometer from JEOL features high sensitivity.
BiOptix announced its four feature true multiplex array instrument with anticipated ship dates in the third quarter of 2009.
Merck & Co. is buying Schering-Plough Corp. for $41.1 billion in stock and cash in a deal that gives the companies more firepower to compete in a drug industry facing slumping sales, tough generic competition, and intense cost pressures.
President Barack Obama is expected to sign an executive order on Monday reversing restrictions on federal funding of embryonic stem cell research.